NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

During the quarter, the Harbor International Compounders Fund returned 4.40%, underperforming its primary benchmark.

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

The childhood obesity epidemic in GCC countries has triggered a debate on the potential use of weight-loss medications such ...

The findings raise questions about the long-term effectiveness of obesity treatment with GLP-1 receptor drugs after initial ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...